Sovelbek® is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 6 years of age and older weighing at least 17 kg.
| DCI | Sofosbuvir/Velpatasvir |
|---|---|
| Dosage | 400/100 mg |
| Trade name | Sovelbek® |
| Name of the originator | Epclusa |
| Presentation | 28 tablets |
| Specialty | Hépatologie-AAD |
